HUN Q1 2026: Recovery Confirmed But Fully Priced In

What happened

Huntsman's Q1 2026 earnings call likely highlighted improving volumes and cost savings, supporting a cyclical recovery narrative. However, the stock has rallied ~16% from the Dec 2025 low of $10.41 to $12.12, now trading nearly double the conservative DCF estimate of $6.27. Net debt/EBITDA remains elevated at ~5.8x with negative interest coverage, and the balance sheet still carries significant risk. The market appears to be pricing in a V-shaped recovery that history suggests is unlikely given European headwinds and structural overcapacity. The Q1 results do not change the fundamental overvaluation; if anything, they reduce the margin of safety further.

Implication

Investors should view the recent rally as an opportunity to exit or underweight. Even with improving fundamentals, the risk/reward is unfavorable: the stock offers little upside from current levels while downside to the DCF anchor (~$6) is nearly 50%. Key watch items include leverage reduction and sustainable FCF generation; until those materialize meaningfully, the equity remains a show-me story at a premium price.

Thesis delta

The report's 'WAIT' stance is upgraded to 'POTENTIAL SELL' as the Q1 2026 earnings call confirms a cyclical recovery that has already been priced in, eliminating the margin of safety. The stock now trades at a significant premium to conservative intrinsic value, and elevated leverage still threatens equity value if the recovery falters. Absent a cheaper entry point or clearer evidence of de-levering, the risk/reward is skewed to the downside.